Leslie Shaw to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Leslie Shaw has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.207
-
Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust W, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. Editorial: How Will Aducanumab Approval Impact AD Research? J Prev Alzheimers Dis. 2021; 8(4):391-392.
Score: 0.150
-
O'Kane D, Davis L, Ardern-Jones M, Laws P, Shaw L, Cork M, Velangi S, Cooper HL, Hudson R, Smith AB, Rout R. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK. Ulster Med J. 2021 May; 90(2):70-76.
Score: 0.039
-
Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM, Harrison L, Morris E, Satwani P, Bhatia M, George D, Bradley MB, Garvin JH, Schwartz J, Baxter-Lowe LA, Cairo MS. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant. 2011 Jun; 46(6):790-9.
Score: 0.018